Erste Asset Management’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.17M | Hold |
235,800
| – | – | 0.02% | 387 |
|
|
2025
Q1 | $1.79M | Hold |
235,800
| – | – | 0.02% | 320 |
|
|
2024
Q4 | $1.99M | Hold |
235,800
| – | – | 0.02% | 325 |
|
|
2024
Q3 | $2.05M | Hold |
235,800
| – | – | 0.02% | 319 |
|
|
2024
Q2 | $1.59M | Hold |
235,800
| – | – | 0.02% | 327 |
|
|
2024
Q1 | $2.2M | Hold |
235,800
| – | – | 0.03% | 292 |
|
|
2023
Q4 | $1.07M | Buy |
235,800
+77,000
| +48% | +$348K | 0.02% | 368 |
|
|
2023
Q3 | $507K | Hold |
158,800
| – | – | 0.01% | 405 |
|
|
2023
Q2 | $805K | Hold |
158,800
| – | – | 0.01% | 378 |
|
|
2023
Q1 | $819K | Hold |
158,800
| – | – | 0.02% | 384 |
|
|
2022
Q4 | $445K | Buy |
158,800
+63,000
| +66% | +$176K | 0.01% | 435 |
|
|
2022
Q3 | $491K | Hold |
95,800
| – | – | 0.01% | 425 |
|
|
2022
Q2 | $373K | Hold |
95,800
| – | – | 0.01% | 457 |
|
|
2022
Q1 | $484K | Hold |
95,800
| – | – | 0.01% | 440 |
|
|
2021
Q4 | $632K | Hold |
95,800
| – | – | 0.01% | 407 |
|
|
2021
Q3 | $971K | Buy |
95,800
+26,000
| +37% | +$264K | 0.02% | 341 |
|
|
2021
Q2 | $960K | Hold |
69,800
| – | – | 0.02% | 346 |
|
|
2021
Q1 | $1.12M | Buy |
69,800
+17,800
| +34% | +$285K | 0.03% | 326 |
|
|
2020
Q4 | $1.04M | Buy |
+52,000
| New | +$1.04M | 0.03% | 331 |
|